| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.033 | 0.6 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |